Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409063 | 0.98 | HTR2C (0.35) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Iodide SCHEMBL11457679 | 0.97 | HTR2C (0.34) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL27986246 | 0.97 | HTR2C (0.34) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6830548 | 0.67 | SLC18A3 (0.37) | — | |
| Hydrochloric Acid SCHEMBL22031619 | 0.66 | — | — | |
| Iodide SCHEMBL11457678 | 0.63 | SLC18A3 (0.37) | — | |
| Iodide SCHEMBL22031617 | 0.62 | — | — | |
| SCHEMBL4907271 | 0.62 | ORAI1 (0.40) | HTR2CHTR2ASLC6A2SLC6A4 | |
| SCHEMBL8331771 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL7936288 | 0.61 | ORAI1 (0.36) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310420-A1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | UNIV MIDWESTERN (US) | 2023-10-05 | — | — | US | disclosed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2890376-B1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | PHARMAZZ INC (US) | 2017-09-27 | — | — | EP | disclosed |
| CN-103989682-B | Use the therapy of centhaquin | Middle West university (US) | 2016-03-30 | — | — | CN | disclosed |
| US-20150250782-A1 | Methods and Compositions for Hypotensive Resuscitation | PHARMAZZ, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| EP-2890376-A1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | Pharmazz, Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| CN-103989682-A | Novel therapeutic treatments using centhaquin | UNIV MIDWESTERN | 2014-08-20 | — | — | CN | disclosed |
| CN-102458399-B | New pharmaceutical use of centhaquin | UNIV MIDWESTERN | 2014-04-23 | — | — | CN | disclosed |
| WO-2014035446-A1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | PHARMAZZ, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| CN-102458399-A | Novel therapeutics using centhaquin | UNIV MIDWESTERN | 2012-05-16 | — | — | CN | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2424529-A2 | NOVEL THERAPEUTIC TREATMENTS USING CENTHAQUIN | Midwestern University (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127096-A2 | NOVEL THERAPEUTIC TREATMENTS USING CENTHAQUIN | MIDWESTERN UNIVERSITY (US) | 2010-11-04 | — | — | WO | disclosed |
| US-6737547-B1 | Compositions containing and methods of using N-acyl-1H-aminoindenes | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2000038673-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING N-ACYL-1H-AMINOINDENES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | SLC6A2 290/4885SLC6A3 2848/4885HTR2C 748/4885 |
| US-20150250782-A1 | Methods and Compositions for Hypotensive Resuscitation | ADRA2A, ADRA2C, ADRB2 | SLC6A2 364/4885SLC6A3 4001/4885HTR2C 1375/4885 |
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | SLC6A2 188/4885SLC6A3 2502/4885HTR2C 680/4885 |
| US-20230310420-A1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | ADRA2A, ADRA2C, ADRB2 | SLC6A2 364/4885SLC6A3 4001/4885HTR2C 1375/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | SLC6A2 290/4885SLC6A3 2848/4885HTR2C 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.